Preventive radiation for early esophagus cancer after chemoradiation
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial tests whether giving preventive (prophylactic) radiation reduces cancer coming back in people with early esophagus cancer after standard chemoradiation. It may help by lowering the chance that microscopic cancer spreads to nearby areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a specific esophagus cancer type (squamous cell, adenosquamous, or basaloid).
- Your cancer is in the chest (thoracic) part of the esophagus.
- Scans show no nearby lymph node spread or distant spread (N0M0) on CT from neck to abdomen.
- Your deepest tumor layer is early (cT1b, such as SM1/SM2/SM3).
- You are 20 years or older and your overall health is good (ECOG score 0–1).
- You have not had prior radiation, and no prior cancer treatment unless it was fully removed with endoscopy (EMR/ESD) under specific conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the best way to treat locally advanced squamous cell esophageal cancer: either chemoradiation followed by planned surgery, or monitoring with surgery only if needed. It may help you choose a strategy that controls the cancer while aiming to reduce unnecessary procedures.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This Phase 2 study tests whether adding an immunotherapy drug (camrelizumab) to standard chemo-radiation can help some people with operable esophagus cancer avoid immediate surgery, using a “watch and wait” approach. If it works, it may reduce the need for early surgery for carefully selected patients.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
This trial tests if adding radiation therapy after endoscopic surgery (ESD) helps people with early-stage esophageal cancer that had certain high-risk features, like deeper invasion or positive margins. It aims to improve outcomes for those who didn't get a complete cure with surgery alone.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.